Spanish consensus on the physical health of patients with depressive disorders

Giner, J.; Ruiz, Jerónimo Saiz; Bobes, Julio; Zamorano, Enric; López, Francisco; Hernando, T; Rico‐Villademoros, Fernando; Álamo, Cecilio; Cervilla, Jorge; Cuadrado, Ángela Ibáñez; Guerra, Elena Ibáñez; López, Sílvia L.; Morán, Pedro; Palao, Diego; Romacho, Montserrat

doi:10.1016/j.rpsmen.2014.10.003

Cited by 5 publications

(3 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is growing interest in the physical health of patients with mental disorders (Giner et al 2014;Bobes et al 2008;De Hert et al 2010). Given the widespread use of antipsychotics (APS) in psychiatric clinical practice, the high frequency of hyperprolactinemia in patients receiving these drugs and their potential consequences, an important aspect of the physical health of patients under antipsychotic treatment is the recognition and management of hyperprolactinemia associated with the use of antipsychotics.…”

Section: Introductionmentioning

confidence: 99%

Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics

Montejo

Arango

Bernardo

et al. 2017

Frontiers in Neuroendocrinology

View full text Add to dashboard Cite

Hyperprolactinemia is an underappreciated/unknown adverse effects of antipsychotics. The consequences of hyperprolactinemia compromise therapeutic adherence and can be serious. We present the consensus recommendations made by a group of experts regarding the management of antipsychotic-induced hyperprolactinemia. The current consensus was developed in 3 phases: 1, review of the scientific literature; 2, subsequent round table discussion to attempt to reach a consensus among the experts; and 3, review by all of the authors of the final conclusions until reaching a complete consensus. We include recommendations on the appropriate time to act after hyperprolactinemia detection and discuss the evidence on available options: decreasing the dose of the antipsychotic drug, switching antipsychotics, adding aripiprazole, adding dopaminergic agonists, and other type of treatment. The consensus also included recommendations for some specific populations such as patients with a first psychotic episode and the pediatric-youth population, bipolar disorder, personality disorders and the elderly population.

show abstract

Section: Introductionmentioning

confidence: 99%

Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics

Montejo

Arango

Bernardo

et al. 2017

Frontiers in Neuroendocrinology

View full text Add to dashboard Cite

show abstract

“…While such relationship has been extensively studied, and although there is an increase in the number of studies where depression is regarded as a result of chronic conditions (93,94), there is also evidence of the inverse relationship. According to longitudinal population-based studies, patients diagnosed with depression are at higher risk for certain medical conditions and for higher degrees of disability as compared to the general population (95). Related to functional condition and chronic clinical burden, older adults with a prior history of depression show faster rates of physical health decline than those who have never suffered from such disorder.…”

Section: Comorbidity and Preventive Aspectsmentioning

confidence: 99%

Depression in the Elderly. Consensus Statement of the Spanish Psychogeriatric Association

et al. 2020

View full text Add to dashboard Cite

Discussion and Conclusions: Consensus was reached for a high number of items as well as for the management of depression in the context of comorbid conditions and in resistant cases. In the current absence of sufficient evidence-based information, our results can be used to inform medical doctors about clinical recommendations that might reduce uncertainty in the diagnosis and treatment of elderly patients with depressive disorders.

show abstract

“…If we take into account that Risperidone is one of the most commonly prescribed antipsychotics, this side effect becomes even more significant (3,4). In the current era of de-institutionalization of patients with serious mental illness with more attention paid to better social engagement and inclusion in work and social activities, numerous studies have shown a higher incidence of poor physical health in patients with mental illness (5,6). Because mental illness affects many aspects of patient's lives, social relations, and daily functioning, the unintended side-effects of Risperidone, such as HPL, may worsen patient's social relationships and interactions and contribute to physical disability.…”

Section: Introductionmentioning

confidence: 99%

Risperidone Induced Hyperprolactinemia: From Basic to Clinical Studies

et al. 2022

View full text Add to dashboard Cite

Risperidone is one of the most commonly used antipsychotics (AP), due to its safety and efficacy in reducing psychotic symptoms. Despite the favorable side effect profile, the therapy is accompanied by side effects due to the non-selectivity of this medicine. This review will briefly highlight the most important basic and clinical findings in this area, consider the clinical effects of AP-induced hyperprolactinemia (HPL), and suggest different approaches to the treatment.The route of application of this drug primarily affects the daily variation and the total concentration of drug levels in the blood, which consequently affects the appearance of side effects, either worsening or even reducing them. Our attention has been drawn to HPL, a frequent but neglected adverse effect observed in cases treated with Risperidone and its secondary manifestations. An increase in prolactin levels above the reference values result in impairment of other somatic functions (lactation, irregular menses, fertility) as well as a significant reduction in quality of life. It has been frequently shown that the side effects of the Risperidone are the most common cause of non-compliance with therapy, resulting in worsening of psychiatric symptoms and hospitalization. However, the mechanism of Risperidone-induced HPL is complicated and still far from fully understood. Most of the preclinical and clinical studies described in this study show that hyperprolactinemia is one of the most common if not the leading side effect of Risperidone therefore to improve the quality of life of these patients, clinicians must recognize and treat HPL associated with the use of these drugs.

show abstract

Spanish consensus on the physical health of patients with depressive disorders

Cited by 5 publications

References 62 publications

Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics

Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics

Depression in the Elderly. Consensus Statement of the Spanish Psychogeriatric Association

Risperidone Induced Hyperprolactinemia: From Basic to Clinical Studies

Contact Info

Product

Resources

About